TNFSF13 anticorps (AA 105-247) (APC)
TNFSF13
Reactivité: Humain
IHC, FACS, IF, ICC
Hôte: Lapin
Polyclonal
APC
N° du produit ABIN5568038
-
-
Antigène
Voir toutes TNFSF13 Anticorps
-
TNFSF13
(Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))
-
Épitope
-
AA 105-247
-
Reactivité
-
Humain
-
Hôte
-
Lapin
-
Clonalité
-
Polyclonal
-
Conjugué
-
Cet anticorp TNFSF13 est conjugé à/à la APC
-
Application
-
Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF), Immunocytochemistry (ICC)
-
Marque
-
AssayLite™
-
Attributs du produit
-
Purified antibody validated for specificity and sensitivity.
-
Purification
-
Affinity Purified
-
Immunogène
-
Human TNFSF13 (105-247 aa) expressed in E. coli
-
Top Product
-
Discover our top product TNFSF13 Anticorps primaire
-
-
-
Indications d'application
-
Optimal working dilution should be determined by the investigator.
-
Restrictions
-
For Research Use only
-
-
Format
-
Lyophilized
-
Buffer
-
Lyophilized from PBS pH 7.4, 20 mg/mL BSA, and 0.02 % Sodium Azide
-
Agent conservateur
-
Sodium azide
-
Précaution d'utilisation
-
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
-
Antigène
-
TNFSF13
(Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))
-
Autre désignation
-
APRIL (TNFSF13 Produits)
-
Synonymes
-
anticorps APRIL, anticorps CD256, anticorps TALL-2, anticorps TALL2, anticorps TRDL-1, anticorps ZTNF2, anticorps 2310026N09Rik, anticorps April, anticorps Tall2, anticorps Trdl1, anticorps SLAN, anticorps ANP32B, anticorps april, anticorps tnf13, anticorps TNLG7B, anticorps TNF superfamily member 13, anticorps tumor necrosis factor (ligand) superfamily, member 13, anticorps acidic leucine-rich nuclear phosphoprotein 32 family member B, anticorps TNFSF13, anticorps Tnfsf13, anticorps LOC494442, anticorps tnfsf13
-
ID gène
-
8741
-
Pathways
-
Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response
-